These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 28246027)
1. Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy. Wu Y; He J; Geng J; An Y; Ye X; Yan S; Yu Q; Yin J; Zhang Z; Li D Eur J Pharmacol; 2017 May; 802():85-92. PubMed ID: 28246027 [TBL] [Abstract][Full Text] [Related]
2. Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy. Wu Y; He J; An Y; Wang X; Liu Y; Yan S; Ye X; Qi J; Zhu S; Yu Q; Yin J; Li D; Wang W J Pharmacol Sci; 2016 Sep; 132(1):24-30. PubMed ID: 27174862 [TBL] [Abstract][Full Text] [Related]
3. Recombinant Newcastle disease virus Anhinga strain (NDV/Anh-EGFP) for hepatoma therapy. Wu Y; Yan S; Lv Z; Chen L; Geng J; He J; Yu Q; Yin J; Ren G; Li D Technol Cancer Res Treat; 2014 Apr; 13(2):169-75. PubMed ID: 23819497 [TBL] [Abstract][Full Text] [Related]
4. The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model. He J; An Y; Qi J; Cui L; Yang K; Liu M; Qu B; Yan S; Yin J; Jing X; Dong H; Yu Q; Li D; Wu Y J Med Virol; 2021 Jun; 93(6):3890-3898. PubMed ID: 32779745 [TBL] [Abstract][Full Text] [Related]
5. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746 [TBL] [Abstract][Full Text] [Related]
6. [Newcastle disease virus enhances tumoricidal activity of mouse NK cells against mouse Novikoff hepatoma cells via up-regulating expression of TRAIL on the NK cells]. Song D; Liang Y; Fan X; Yin J; Gong J; Lai Z; Gao L Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 May; 31(5):599-604. PubMed ID: 25940284 [TBL] [Abstract][Full Text] [Related]
7. Newcastle disease virus chimeras expressing the Hemagglutinin- Neuraminidase protein of mesogenic strain exhibits an enhanced anti-hepatoma efficacy. He J; Pan Z; Tian G; Liu X; Liu Y; Guo X; An Y; Song L; Wu H; Cao H; Yu D; Che R; Xu P; Rasoul LM; Li D; Yin J Virus Res; 2016 Aug; 221():23-9. PubMed ID: 27164362 [TBL] [Abstract][Full Text] [Related]
8. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model. El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307 [TBL] [Abstract][Full Text] [Related]
9. Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model. An Y; Liu T; He J; Wu H; Chen R; Liu Y; Wu Y; Bai Y; Guo X; Zheng Q; Liu C; Yin J; Li D; Ren G J Biomed Sci; 2016 Jul; 23(1):55. PubMed ID: 27465066 [TBL] [Abstract][Full Text] [Related]
10. TRAIL is involved in the tumoricidal activity of mouse natural killer cells stimulated by Newcastle disease virus in vitro. Song DZ; Liang Y; Xiao Q; Yin J; Gong JL; Lai ZP; Zhang ZF; Gao LX; Fan XH Anat Rec (Hoboken); 2013 Oct; 296(10):1552-60. PubMed ID: 23959779 [TBL] [Abstract][Full Text] [Related]
11. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene. Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282 [TBL] [Abstract][Full Text] [Related]
12. Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice. Wei D; Li Q; Wang XL; Wang Y; Xu J; Feng F; Nan G; Wang B; Li C; Guo T; Chen ZN; Bian H J Exp Clin Cancer Res; 2015 Dec; 34():153. PubMed ID: 26689432 [TBL] [Abstract][Full Text] [Related]
13. Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting. Wu Q; Jin Y; Li S; Guo X; Sun W; Liu J; Li Q; Niu D; Zou Y; Du X; Li Y; Zhao T; Li Z; Li X; Ren G Int Immunopharmacol; 2024 Jul; 136():112305. PubMed ID: 38823178 [TBL] [Abstract][Full Text] [Related]
14. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. Elankumaran S; Rockemann D; Samal SK J Virol; 2006 Aug; 80(15):7522-34. PubMed ID: 16840332 [TBL] [Abstract][Full Text] [Related]
15. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma. Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790 [TBL] [Abstract][Full Text] [Related]
16. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma. Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179 [TBL] [Abstract][Full Text] [Related]
17. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy. Bai F; Niu Z; Tian H; Li S; Lv Z; Zhang T; Ren G; Li D Immunol Lett; 2014; 159(1-2):36-46. PubMed ID: 24613899 [TBL] [Abstract][Full Text] [Related]
18. Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy. Ren G; Tian G; Liu Y; He J; Gao X; Yu Y; Liu X; Zhang X; Sun T; Liu S; Yin J; Li D Technol Cancer Res Treat; 2016 Oct; 15(5):NP83-94. PubMed ID: 26303327 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma. Galal El-Shemi A; Mohammed Ashshi A; Oh E; Jung BK; Basalamah M; Alsaegh A; Yun CO Gene Ther; 2018 Jan; 25(1):54-65. PubMed ID: 28925992 [TBL] [Abstract][Full Text] [Related]
20. Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Altomonte J; Marozin S; Schmid RM; Ebert O Mol Ther; 2010 Feb; 18(2):275-84. PubMed ID: 19809404 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]